United Therapeutics CEO Martine Rothblatt Buys Shares
CEO Martine Rothblatt purchased 9,500 shares of United Therapeutics, boosting confidence in the company.
Key Points
- Martine Rothblatt, CEO of United Therapeutics, acquired 9,500 shares at $146.03 each, totaling a transaction value of $1.39 million.
- United Therapeutics, trading at $548.27, has a market cap of $23.27 billion and a P/E ratio of 20.28, with recent analyst upgrades.
- BlackRock, Inc. and Avoro Capital Advisors LLC increased their stakes, while Wellington Management Group reduced its holdings.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Martine Rothblatt, the Chairperson and CEO of United Therapeutics Corporation, purchased 9,500 shares of the company on June 16, 2026. The shares were bought at an average price of $146.03 each, amounting to a total transaction value of approximately $1.39 million. This move by Rothblatt is seen as a strong signal of confidence in United Therapeutics' future prospects.
Other Institutional Activity in United Therapeutics
Several major institutional investors have also made moves in United Therapeutics recently. BlackRock, Inc. increased its holdings by 228,883 shares, bringing its total to nearly 5.4 million shares valued at about $3.2 billion. Avoro Capital Advisors LLC added 23,940 shares, totaling 2.63 million shares worth approximately $1.56 billion. On the other hand, Wellington Management Group reduced its position by 177,245 shares, leaving it with 2.26 million shares valued at $1.34 billion. Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both initiated new positions, each acquiring over 1.95 million shares.
United Therapeutics Corporation Stock Up 7.0%
Shares of United Therapeutics, traded on the NasdaqGS under the ticker UTHR, are currently priced at $548.27. The company boasts a market capitalization of about $23.27 billion and has a P/E ratio of 20.28. It has a 52-week low of $272.12 and a high of $609.35. The stock's 50-day moving average stands at $566.59, and the 200-day moving average is $495.58. United Therapeutics maintains a strong financial position with a current ratio of 4.79 and a quick ratio of 4.12.
$UTHR stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
United Therapeutics reported revenues of approximately $3.17 billion, though this reflects a slight decline of 1.6% from previous periods. The company maintains a robust net margin of 40.62% and a return on equity of 20.26%. The next earnings report is anticipated on July 29, 2026.
Insider Buying and Selling at United Therapeutics Corporation
In addition to Rothblatt's recent purchase, CFO and Treasurer James Edgemond acquired 10,000 shares on June 15, 2026, at an average price of $117.76. These insider transactions highlight the leadership's positive outlook on the company's growth.
Analysts Set New Price Targets
Analysts have shown optimism about United Therapeutics' prospects. On May 7, 2026, RBC Capital maintained a 'buy' rating with a price target of $701. Wells Fargo upgraded the stock to a 'buy' with a target of $738 on the same day. The consensus among 13 analysts is a 'buy' recommendation, with a mean target price set at $665.23.
About United Therapeutics
United Therapeutics Corporation, headquartered in Silver Spring, Maryland, is a biotechnology company that focuses on developing and commercializing products for patients with chronic and life-threatening conditions. The company offers a range of therapies, including treatments for pulmonary arterial hypertension and high-risk neuroblastoma. With approximately 1,400 employees, United Therapeutics continues to innovate in the healthcare sector under the leadership of CEO Martine Rothblatt.
Bottom Line
Martine Rothblatt's recent purchase of United Therapeutics shares signals strong confidence in the company's trajectory. Investors often track insider transactions as they can provide insights into the company's future performance. While this 13F filing provides a snapshot of past activity, it is important to remember that it may not reflect current positions.
Get United Therapeutics Corporation alerts
New 13F filings, insider trades, and analyst moves on $UTHR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.